News | May 07, 2021
Lonza announces expansion plans for mammalian manufacturing facilities
The facility is expected to be completed in 2024
The facility is expected to be completed in 2024
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The price increases are due to the rising costs of raw materials.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
